World-first Australian test could predict CAD prognosis

Patients with the highest levels of the ACE2 enzyme are at highest risk



In a world first, researchers have shown that measuring a particular enzyme in plasma could predict the risk of events in patients with severe coronary artery disease (CAD).

An Austin Health and University of Melbourne study found patients with obstructive CAD who had the highest levels of the ACE2 enzyme were more than twice as likely to experience a major adverse cardiac event.

ACE2 circulates in low quantities in healthy people but its presence has long been associated with cardiovascular risk such